EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma
← catalyst calendarSponsored by NovoCure Ltd. (industry) · NVCR — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
84actual
Sites
15
Countries
Czechia, Germany, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-28 | actual | When the study began enrolling |
| Primary completion | 2025-11-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-18 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
- Device: Tumor Treating Fields — also filed as NovoTTF-200T
- Drug: Atezolizumab — also filed as Tecentriq (Brand name)
- Drug: Gemcitabine — also filed as Gemzar
- Drug: nab-paclitaxel — also filed as Abraxane
Primary outcome
what the primary-completion date above is the date OFDisease control rate (DCR)
measured at least 16 weeks for SD or confirmed PR/CR
Permalink · NVCR's whole pipeline · Catalyst calendar · Every registered study · What changed